2023 was a tricky year for the biopharma field, with many businesses downsizing and restructuring their workforces to stay afloat. There are indications of recovery, as mergers and acquisitions picked up throughout the pharmaceutical and daily life sciences marketplace from the latter Element of 2023 and also have continued their https://sites.google.com/view/bio-sites/blog